BioCatalystWatch
PGENWorkspace / PGEN / OverviewCompany library
Price
Market cap
Next catalystExpected 2026PAPZIMEOS — planned pediatric RRP study · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Other pipelines

PRGN-2009

HPV-16 antigens × HPV-18 antigens

PreINDP1P2P3FilingApproved
PRGN-3006

CD33

PreINDP1P2P3FilingApproved
PRGN-2009

HPV-16 antigens × HPV-18 antigens

PreINDP1P2P3FilingApproved
PRGN-3008

CD19 × PD-1

PreINDP1P2P3FilingApproved
PRGN-2013

HBV antigens

PreINDP1P2P3FilingApproved
Next Generation MSLN UltraCAR-T

Mesothelin (MSLN) × PD-1

PreINDP1P2P3FilingApproved
PRGN-3008

CD19 × PD-1

PreINDP1P2P3FilingApproved

Approved / commercial

History / paused

Human proinsulin (hPINS/PPI)

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

PGEN SEC archive